Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daxibotulinumtoxin A - Revance Therapeutics

Next Previous
Drug Profile

Daxibotulinumtoxin A - Revance Therapeutics

Alternative Names: DAXI; Daxibotulinumtoxin-A; DaxibotulinumtoxinA for Injection; DaxibotulinumtoxinA-lanm; DAXXIFY; RT-002

Latest Information Update: 14 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Revance Therapeutics
  • Developer Revance Therapeutics; Shanghai Fosun Pharmaceutical
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antispasmodics; Antispastics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Peptide drug conjugates; Skin disorder therapies; Urologics
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Torticollis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glabellar lines; Torticollis
  • Phase II Muscle spasticity
  • No development reported Skin disorders
  • Discontinued Plantar fasciitis

Most Recent Events

  • 12 Feb 2025 Revance Therapeutics completes a phase II trial for Glabellar lines in USA (IM, Injection) (NCT06411002)
  • 09 Sep 2024 Registered for Glabellar lines in China (IM)
  • 09 May 2024 Launched for Torticollis in USA (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top